HRP20110599T1 - Antitijela protiv toksina clostridium difficile i njihove primjene - Google Patents

Antitijela protiv toksina clostridium difficile i njihove primjene Download PDF

Info

Publication number: HRP20110599T1
Authority: HR; Croatia
Prior art keywords: antibody; antigen; seq; nos; variable region
Prior art date: 2004-02-06

Application number

HR20110599T

Other languages

English (en)

Croatian (hr)

Inventor

Ambrosino Donna

J. Babcock Gregory

Broering Theresa

Graziano Robert

Javier Hernandez Hector

Lowy Israel

Mandell Robert

Molrine Deborah

D. Thomas William

Zhang Hui-Fen

Original Assignee

University Of Massachusetts

Medarex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-06

Filing date

2011-08-11

Publication date

2011-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110599(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-11 Application filed by University Of Massachusetts, Medarex filed Critical University Of Massachusetts

2011-10-31 Publication of HRP20110599T1 publication Critical patent/HRP20110599T1/hr

Links

241000193163 Clostridioides difficile Species 0.000 title claims abstract 14
239000003053 toxin Substances 0.000 title 1
231100000765 toxin Toxicity 0.000 title 1
108700012359 toxins Proteins 0.000 title 1
239000000427 antigen Substances 0.000 claims abstract 31
108091007433 antigens Proteins 0.000 claims abstract 31
102000036639 antigens Human genes 0.000 claims abstract 31
101100112922 Candida albicans CDR3 gene Proteins 0.000 claims abstract 14
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 11
101710084578 Short neurotoxin 1 Proteins 0.000 claims abstract 2
101710182532 Toxin a Proteins 0.000 claims abstract 2
239000000203 mixture Substances 0.000 claims 13
101710182223 Toxin B Proteins 0.000 claims 9
239000003814 drug Substances 0.000 claims 5
229940124597 therapeutic agent Drugs 0.000 claims 5
102000039446 nucleic acids Human genes 0.000 claims 3
108020004707 nucleic acids Proteins 0.000 claims 3
150000007523 nucleic acids Chemical class 0.000 claims 3
241001465754 Metazoa Species 0.000 claims 2
230000003115 biocidal effect Effects 0.000 claims 2
239000003795 chemical substances by application Substances 0.000 claims 2
239000003550 marker Substances 0.000 claims 2
239000006041 probiotic Substances 0.000 claims 2
230000000529 probiotic effect Effects 0.000 claims 2
235000018291 probiotics Nutrition 0.000 claims 2
229960005486 vaccine Drugs 0.000 claims 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
108010001478 Bacitracin Proteins 0.000 claims 1
108010059993 Vancomycin Proteins 0.000 claims 1
239000003242 anti bacterial agent Substances 0.000 claims 1
229960003071 bacitracin Drugs 0.000 claims 1
229930184125 bacitracin Natural products 0.000 claims 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
230000001268 conjugating effect Effects 0.000 claims 1
238000002405 diagnostic procedure Methods 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000013604 expression vector Substances 0.000 claims 1
108010074605 gamma-Globulins Proteins 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
238000000034 method Methods 0.000 claims 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
229960000282 metronidazole Drugs 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
229920001184 polypeptide Polymers 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 claims 1
229960002181 saccharomyces boulardii Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
229940031572 toxoid vaccine Drugs 0.000 claims 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
229960003165 vancomycin Drugs 0.000 claims 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
-1 wherein the antibody Proteins 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)

HR20110599T 2004-02-06 2011-08-11 Antitijela protiv toksina clostridium difficile i njihove primjene HRP20110599T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US54235704P	2004-02-06	2004-02-06
US61385404P	2004-09-28	2004-09-28
PCT/US2005/003725 WO2006121422A2 (en)	2004-02-06	2005-02-04	Antibodies against clostridium difficile toxins and uses thereof

Publications (1)

Publication Number	Publication Date
HRP20110599T1 true HRP20110599T1 (hr)	2011-10-31

Family

ID=36928722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20110599T HRP20110599T1 (hr)	2004-02-06	2011-08-11	Antitijela protiv toksina clostridium difficile i njihove primjene

Country Status (28)

Country	Link
US (8)	US7625559B2 (ja)
EP (3)	EP1766093B1 (ja)
JP (3)	JP4588763B2 (ja)
KR (3)	KR101332927B1 (ja)
CN (1)	CN101014620B (ja)
AT (1)	ATE512986T1 (ja)
AU (1)	AU2005320349C1 (ja)
BE (1)	BE2017C023I2 (ja)
BR (1)	BRPI0507433C1 (ja)
CA (1)	CA2553946C (ja)
CY (3)	CY1111860T1 (ja)
DK (3)	DK2270045T3 (ja)
ES (3)	ES2533492T3 (ja)
HK (3)	HK1102287A1 (ja)
HR (1)	HRP20110599T1 (ja)
HU (3)	HUE024962T2 (ja)
LT (2)	LT2857418T (ja)
LU (1)	LUC00025I2 (ja)
MX (1)	MXPA06008839A (ja)
NL (1)	NL300881I2 (ja)
NO (2)	NO340300B1 (ja)
NZ (2)	NZ580828A (ja)
PL (3)	PL1766093T3 (ja)
PT (3)	PT1766093E (ja)
RS (1)	RS51908B (ja)
SI (3)	SI2270045T1 (ja)
WO (1)	WO2006121422A2 (ja)
ZA (1)	ZA200606516B (ja)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
NZ580828A (en)	2004-02-06	2011-09-30	Univ Massachusetts	Antibodies against clostridium difficile toxin B and uses thereof
CN101906152B (zh) *	2004-06-28	2013-06-05	独立行政法人科学技术振兴机构	STX2抑制性肽以及Vero毒素中和剂
WO2006071877A2 (en) *	2004-12-27	2006-07-06	Progenics Pharmaceuticals (Nevada), Inc.	Orally deliverable and anti-toxin antibodies and methods for making and using them
RU2465893C2 (ru) *	2006-08-02	2012-11-10	Йоханнес Гутенберг-Университет Майнц	Лекарственное средство от отравлений
WO2008094538A2 (en)	2007-01-30	2008-08-07	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
AU2014201846B2 (en) *	2007-01-30	2016-07-07	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
US20080188007A1 (en) *	2007-02-06	2008-08-07	Meridian Life Science, Inc.	Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) *	2008-05-26	2012-12-19	北京庄笛浩禾生物医学科技有限公司	一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
US8420784B2 (en) *	2008-05-27	2013-04-16	Kyowa Hakko Kirin Co., Ltd.	Interleukin 10 receptor, (IL-10R) antibodies
DE102008029688B4 (de) *	2008-06-24	2016-06-23	Biodics Gmbh	Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
US8709428B2 (en)	2009-02-20	2014-04-29	Health Protection Agency	Antibodies to Clostridium difficile toxins
EP2459588B1 (de) *	2009-07-27	2016-06-29	BioDics GmbH	Verfahren zum nachweis und zur identifikation eines varianten c. difficile stammes in einer probe
US8889363B2 (en)	2009-07-27	2014-11-18	Biodics	Method for the detection and identification of a variant C. difficile strain in a sample
WO2011063346A1 (en) *	2009-11-20	2011-05-26	Northshore University Health System Research Institute	Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) *	2009-12-04	2010-01-20	Health Prot Agency	Therapies for preventing or suppressing clostridium difficile infection
RU2630663C9 (ru) *	2010-04-15	2017-11-29	Проджиникс Фармасьютикалс, Инк.	Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
JP5965389B2 (ja) *	2010-04-15	2016-08-03	プロゲニクスファーマシューティカルズインコーポレーテッドＰｒｏｇｅｎｉｃｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
DK2753352T4 (da) *	2010-09-03	2022-09-12	Valneva Austria Gmbh	Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
GB201016742D0 (en) *	2010-10-05	2010-11-17	Health Prot Agency	Clostridium difficile antigens
EP2632949B1 (en) *	2010-10-25	2017-09-13	National Research Council of Canada	Clostridium difficile-specific antibodies and uses thereof
WO2012092469A2 (en) *	2010-12-29	2012-07-05	Cangene Corporation	Clostridium difficile antigens
WO2012118693A1 (en)	2011-02-28	2012-09-07	Northshore University Healthsystem	Methods of diagnosing clostridium difficile infection
MX347521B (es)	2011-04-22	2017-04-27	Wyeth Llc	Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
CA2846486C (en) *	2011-07-12	2019-08-20	Philadelphia Health & Education Corporation	Novel clostridium difficile dna vaccine
SG10201804809RA (en)	2011-08-22	2018-07-30	Cnj Holdings Inc	Clostridium difficile antibodies
PT2758432T (pt)	2011-09-16	2019-06-14	Ucb Biopharma Sprl	Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
CA2856085C (en)	2011-11-18	2020-06-30	National Research Council Of Canada	Clostridium difficile lipoteichoic acid and uses thereof
ES2704069T3 (es)	2011-12-08	2019-03-14	Glaxosmithkline Biologicals Sa	Vacuna basada en toxinas de Clostridium difficile
DE102011121238A1 (de) *	2011-12-14	2013-06-20	Universitätsklinikum Hamburg-Eppendorf	Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es)	2012-01-27	2014-09-17	Merck Sharp & Dohme	Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CN108101983A (zh) *	2012-03-02	2018-06-01	瑞泽恩制药公司	艰难梭状芽孢杆菌毒素的人源抗体
GB201206070D0 (en)	2012-04-04	2012-05-16	Health Prot Agency	Clostridium difficile antigens
EP2921502A4 (en) *	2012-10-19	2016-09-28	Evec Inc	AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
BR122016023101B1 (pt) *	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013352034B2 (en) *	2012-11-28	2018-08-02	Emergent Biosolutions Canada Inc.	Antibodies against Clostridium difficile
WO2014144292A2 (en)	2013-03-15	2014-09-18	Sanofi Pasteur Biologics , Llc	Antibodies against clostridium difficile toxins and methods of using the same
CN105555309A (zh) *	2013-04-19	2016-05-04	英穆伦有限公司	治疗和/或预防艰难梭菌相关疾病的方法和组合物
US9181632B1 (en)	2013-09-09	2015-11-10	Merck Sharp & Dohme Corp.	C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) *	2013-12-26	2015-07-02	Tufts University	Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
WO2015120474A1 (en) *	2014-02-10	2015-08-13	Igm Biosciences, Inc.	Iga multi-specific binding molecules
EP3145546B1 (en)	2014-02-19	2020-12-09	Emergent BioSolutions Canada Inc.	Marburg monoclonal antibodies
AU2015243246B2 (en)	2014-04-10	2018-09-06	Obi Pharma Inc.	Antibodies, pharmaceutical compositions and uses thereof
US10550437B2 (en) *	2014-05-30	2020-02-04	Case Western Reserve University	Clostridium difficile culture medium
US10513552B2 (en)	2014-06-20	2019-12-24	Immunimed Inc.	Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en)	2014-06-20	2019-04-17	Immunimed Inc.	Polyclonal antibodies against clostridium difficile and uses thereof
ES2870506T3 (es) *	2015-02-19	2021-10-27	Immune Biosolutions Inc	Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
EP3277706A1 (en)	2015-03-31	2018-02-07	VHsquared Limited	Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
WO2016156474A1 (en)	2015-03-31	2016-10-06	Vhsquared Limited	Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
CN105039262B (zh) *	2015-07-10	2018-07-03	北京科兴中维生物技术有限公司	破伤风类毒素单克隆抗体及其应用
CA3002789A1 (en)	2015-09-04	2017-03-09	Primatope Therapeutics Inc.	Humanized anti-cd40 antibodies and uses thereof
PL3390441T3 (pl)	2015-12-15	2022-01-10	Gilead Sciences, Inc.	Przeciwciała neutralizujące ludzki wirus niedoboru odporności
US11299751B2 (en)	2016-04-29	2022-04-12	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
WO2018035407A1 (en) *	2016-08-19	2018-02-22	Enbiotix, Inc.	Bacteriophages for neutralizing toxins and methods of use thereof
AR112257A1 (es)	2017-06-21	2019-10-09	Gilead Sciences Inc	Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
CN112740017A (zh) *	2018-04-19	2021-04-30	曙光诊断学公司	靶标检测
US20220226430A1 (en) *	2019-05-11	2022-07-21	The Texas A&M University System	Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) *	2020-04-30	2021-11-04	Gottfried Himmler	Anti-toxin secretory iga2 preparation
CN111499738B (zh) *	2020-06-03	2022-04-05	郑州师范学院	一种抗艰难梭菌肠毒素a的抗体
CN114853896B (zh) *	2020-11-30	2023-05-09	四川大学华西医院	一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN117720651B (zh) *	2023-12-13	2024-05-31	北京新兴四寰生物技术有限公司	抗艰难梭菌毒素b的单克隆抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4879218A (en)	1982-09-13	1989-11-07	Virginia Tech Intellectual Properties, Inc.	Antibody for C.difficile
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5358868A (en)	1987-11-24	1994-10-25	Connaught Laboratories Limited	Genetic detoxification of pertussis toxin
GB8727489D0 (en)	1987-11-24	1987-12-23	Connaught Lab	Detoxification of pertussis toxin
US5221618A (en)	1987-11-24	1993-06-22	Connaught Laboratories Limited	Genetic detoxification of pertussis toxin
US5244657A (en)	1987-11-24	1993-09-14	Connaught Laboratories Limited	Genetic detoxification of pertussis toxin
US5332583A (en)	1987-11-24	1994-07-26	Connaught Laboratories Limited	Vaccine containing genetically-detoxified pertussis holotoxin
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5601823A (en)	1989-10-31	1997-02-11	Ophidian Pharmaceuticals, Inc.	Avian antitoxins to clostridium difficle toxin A
US5919665A (en) *	1989-10-31	1999-07-06	Ophidian Pharmaceuticals, Inc.	Vaccine for clostridium botulinum neurotoxin
US5736139A (en) *	1989-10-31	1998-04-07	Ochidian Pharmaceuticals, Inc.	Treatment of Clostridium difficile induced disease
US5231003A (en) *	1990-05-11	1993-07-27	Cambridge Bioscience Corporation	Monoclonal antibodies specific for toxin b of clostridium difficile
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) *	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en)	1993-04-26	1994-11-10	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en)	1990-08-29	2005-07-27	GenPharm International, Inc.	Transgenic mice capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) *	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
EP0593592B1 (en)	1991-07-08	1998-03-25	The University Of Massachusetts At Amherst	Thermotropic liquid crystal segmented block copolymer
EP0618970A1 (en) *	1991-12-10	1994-10-12	Dana Farber Cancer Institute	Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
US5466672A (en)	1992-12-04	1995-11-14	Ophidian Pharmaceuticals, Inc.	Therapeutic use of clostridium difficile toxin A
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
CZ296806B6 (cs)	1994-10-24	2006-06-14	Allergan, Inc.	Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu
GB9621295D0 (en) *	1995-12-07	1996-11-27	Cambridge Antibody Tech	Specific binding members,materials and methods
AU746859B2 (en)	1997-06-20	2002-05-02	Imperial College Of Science, Technology And Medicine	Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) *	1997-09-10	1999-03-11	Eichel Streiber Christoph Von	Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
AU754270B2 (en) *	1997-10-20	2002-11-07	Sanofi Pasteur Biologics, Llc	Passive immunization against clostridium difficile disease
US6733760B1 (en) *	1999-04-09	2004-05-11	Techlab, Inc.	Recombinant toxin A/toxin B vaccine against Clostridium difficile
IL147765A0 (en)	1999-07-29	2002-08-14	Medarex Inc	HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
IL148079A0 (en)	1999-08-24	2002-09-12	Medarex Inc	Human ctla-4 antibodies and compositions containing the same
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
EP2990420B1 (en)	2000-05-26	2016-12-21	Immunex Corporation	Use of interleukin-4 receptor antibodies and compositions thereof
UA81743C2 (uk) *	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) *	2001-08-01	2010-12-11	Centocor Inc	Anti-tnf antibodies, compositions, methods and uses
NZ534687A (en) *	2002-01-28	2007-10-26	Medarex Inc	Human monoclonal antibodies to prostate specific membrane antigen (PSMA) seq id 54
JP2005526506A (ja) *	2002-03-04	2005-09-08	イムクローンシステムズインコーポレイティド	Ｋｄｒに特異的なヒト抗体及びその利用
US7262277B2 (en) *	2002-03-21	2007-08-28	Eli Lilly And Company	Antagonistic anti-hFAS ligand human antibodies and fragments thereof
CA2484930A1 (en)	2002-05-06	2003-11-13	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7396913B2 (en) *	2002-10-14	2008-07-08	Abbott Laboratories	Erythropoietin receptor binding antibodies
TWI320716B (en) *	2002-10-14	2010-02-21	Abbott Lab	Erythropoietin receptor binding antibodies
CN100434440C (zh) *	2002-12-02	2008-11-19	阿布格尼克斯公司	针对肿瘤坏死因子的抗体及其用途
WO2004055050A2 (en)	2002-12-10	2004-07-01	Endocube Sas	Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070003561A1 (en) *	2003-07-08	2007-01-04	Sorensen Anders P	Binding member towards pneumococcus surface adhesin a protein (psaa)
EP2865687A1 (en) *	2003-12-10	2015-04-29	E. R. Squibb & Sons, L.L.C.	IP-10 antibodies and their uses
NZ580828A (en)	2004-02-06	2011-09-30	Univ Massachusetts	Antibodies against clostridium difficile toxin B and uses thereof
IT1395574B1 (it)	2009-09-14	2012-10-16	Guala Dispensing Spa	Dispositivo di erogazione

2005
- 2005-02-04 NZ NZ580828A patent/NZ580828A/en unknown
- 2005-02-04 EP EP05857759A patent/EP1766093B1/en active Active
- 2005-02-04 MX MXPA06008839A patent/MXPA06008839A/es active IP Right Grant
- 2005-02-04 SI SI200531949T patent/SI2270045T1/sl unknown
- 2005-02-04 CA CA2553946A patent/CA2553946C/en active Active
- 2005-02-04 BR BRPI0507433A patent/BRPI0507433C1/pt active IP Right Grant
- 2005-02-04 HU HUE10010733A patent/HUE024962T2/en unknown
- 2005-02-04 ES ES10010733.3T patent/ES2533492T3/es active Active
- 2005-02-04 AU AU2005320349A patent/AU2005320349C1/en active Active
- 2005-02-04 NZ NZ548821A patent/NZ548821A/en unknown
- 2005-02-04 EP EP10010733.3A patent/EP2270045B8/en active Active
- 2005-02-04 AT AT05857759T patent/ATE512986T1/de active
- 2005-02-04 DK DK10010733.3T patent/DK2270045T3/en active
- 2005-02-04 KR KR1020117029761A patent/KR101332927B1/ko active IP Right Grant
- 2005-02-04 PL PL05857759T patent/PL1766093T3/pl unknown
- 2005-02-04 PT PT05857759T patent/PT1766093E/pt unknown
- 2005-02-04 DK DK14194551.9T patent/DK2857418T3/en active
- 2005-02-04 US US11/051,453 patent/US7625559B2/en active Active
- 2005-02-04 SI SI200531344T patent/SI1766093T1/sl unknown
- 2005-02-04 DK DK05857759.4T patent/DK1766093T3/da active
- 2005-02-04 EP EP14194551.9A patent/EP2857418B1/en active Active
- 2005-02-04 PT PT100107333T patent/PT2270045E/pt unknown
- 2005-02-04 PL PL10010733T patent/PL2270045T3/pl unknown
- 2005-02-04 LT LTEP14194551.9T patent/LT2857418T/lt unknown
- 2005-02-04 HU HUE14194551A patent/HUE034552T2/en unknown
- 2005-02-04 ES ES14194551.9T patent/ES2643760T3/es active Active
- 2005-02-04 PT PT141945519T patent/PT2857418T/pt unknown
- 2005-02-04 KR KR1020067017771A patent/KR101332994B1/ko active IP Right Grant
- 2005-02-04 KR KR1020127017138A patent/KR20120083534A/ko not_active Application Discontinuation
- 2005-02-04 PL PL14194551T patent/PL2857418T3/pl unknown
- 2005-02-04 WO PCT/US2005/003725 patent/WO2006121422A2/en active Application Filing
- 2005-02-04 JP JP2007527193A patent/JP4588763B2/ja active Active
- 2005-02-04 SI SI200532173T patent/SI2857418T1/en unknown
- 2005-02-04 ES ES05857759T patent/ES2366626T3/es active Active
- 2005-02-04 CN CN2005800041265A patent/CN101014620B/zh active Active
- 2005-02-04 RS RS20110361A patent/RS51908B/en unknown
2006
- 2006-08-04 ZA ZA2006/06516A patent/ZA200606516B/en unknown
- 2006-08-23 NO NO20063767A patent/NO340300B1/no active Protection Beyond IP Right Term
2007
- 2007-09-25 HK HK07110397.1A patent/HK1102287A1/xx unknown
- 2007-09-25 HK HK11105869.4A patent/HK1152048A1/xx unknown
2009
- 2009-07-31 US US12/533,501 patent/US8236311B2/en active Active
- 2009-07-31 US US12/533,552 patent/US8257709B2/en active Active
2010
- 2010-07-28 JP JP2010169364A patent/JP5319622B2/ja active Active
2011
- 2011-08-11 HR HR20110599T patent/HRP20110599T1/hr unknown
- 2011-09-13 CY CY20111100872T patent/CY1111860T1/el unknown
2012
- 2012-06-07 US US13/490,757 patent/US8609111B2/en active Active
2013
- 2013-02-27 JP JP2013036855A patent/JP5717300B2/ja active Active
- 2013-11-14 US US14/080,598 patent/US9217029B2/en active Active
2015
- 2015-09-24 HK HK15109420.4A patent/HK1208873A1/xx unknown
- 2015-10-29 US US14/926,706 patent/US20160152694A1/en not_active Abandoned
2017
- 2017-06-27 HU HUS1700028C patent/HUS1700028I1/hu unknown
- 2017-06-27 NL NL300881C patent/NL300881I2/nl unknown
- 2017-06-28 CY CY2017022C patent/CY2017022I1/el unknown
- 2017-06-28 BE BE2017C023C patent/BE2017C023I2/fr unknown
- 2017-07-04 LU LU00025C patent/LUC00025I2/en unknown
- 2017-07-07 NO NO2017032C patent/NO2017032I1/no unknown
- 2017-07-11 LT LTPA2017022 patent/LTC2270045I2/lt unknown
- 2017-09-21 CY CY20171101001T patent/CY1119416T1/el unknown
2018
- 2018-03-19 US US15/924,703 patent/US20180208643A1/en not_active Abandoned
2020
- 2020-09-16 US US17/022,766 patent/US20210269511A1/en not_active Abandoned

Also Published As

Publication number	Publication date
LT2857418T (lt)	2017-09-25
NO340300B1 (no)	2017-03-27
EP2270045B1 (en)	2014-12-31
JP2007533330A (ja)	2007-11-22
EP2857418B1 (en)	2017-07-26
AU2005320349A1 (en)	2006-08-24
US9217029B2 (en)	2015-12-22
US20140120614A1 (en)	2014-05-01
KR101332927B1 (ko)	2013-11-26
MXPA06008839A (es)	2008-03-07
RS51908B (en)	2012-02-29
CY2017022I2 (el)	2017-11-14
SI2857418T1 (en)	2018-01-31
CY2017022I1 (el)	2017-11-14
US20180208643A1 (en)	2018-07-26
US20210269511A1 (en)	2021-09-02
EP2270045A1 (en)	2011-01-05
KR101332994B1 (ko)	2013-11-26
BRPI0507433B1 (pt)	2018-03-20
ES2533492T3 (es)	2015-04-10
WO2006121422A8 (en)	2007-04-26
BE2017C023I2 (ja)	2024-08-08
EP2270045B8 (en)	2015-02-25
JP2013153750A (ja)	2013-08-15
KR20070050863A (ko)	2007-05-16
CA2553946C (en)	2019-02-26
JP2011019516A (ja)	2011-02-03
US20120288508A1 (en)	2012-11-15
CA2553946A1 (en)	2005-08-06
PT1766093E (pt)	2011-08-24
LUC00025I2 (ja)	2017-09-08
ATE512986T1 (de)	2011-07-15
HUS1700028I1 (hu)	2017-07-28
WO2006121422A2 (en)	2006-11-16
AU2005320349B8 (en)	2010-04-22
DK2857418T3 (en)	2017-10-23
LUC00025I1 (ja)	2017-07-06
US8236311B2 (en)	2012-08-07
KR20120083534A (ko)	2012-07-25
ES2643760T3 (es)	2017-11-24
PL2857418T3 (pl)	2017-10-31
US8609111B2 (en)	2013-12-17
KR20120003017A (ko)	2012-01-09
AU2005320349A8 (en)	2008-08-07
US20100233182A1 (en)	2010-09-16
HK1102287A1 (en)	2007-11-09
HK1208873A1 (en)	2016-03-18
US7625559B2 (en)	2009-12-01
DK1766093T3 (da)	2011-10-03
LTC2270045I2 (lt)	2019-12-10
CN101014620B (zh)	2012-05-09
US8257709B2 (en)	2012-09-04
ES2366626T3 (es)	2011-10-24
SI2270045T1 (sl)	2015-06-30
US20160152694A1 (en)	2016-06-02
NL300881I2 (nl)	2024-07-16
JP4588763B2 (ja)	2010-12-01
PL2270045T3 (pl)	2015-06-30
SI1766093T1 (sl)	2011-12-30
LTPA2017022I1 (lt)	2017-09-11
ZA200606516B (en)	2011-01-26
EP2857418A1 (en)	2015-04-08
EP1766093B1 (en)	2011-06-15
HK1152048A1 (en)	2012-02-17
NZ548821A (en)	2009-12-24
JP5319622B2 (ja)	2013-10-16
CY1111860T1 (el)	2015-11-04
US20100233181A1 (en)	2010-09-16
JP5717300B2 (ja)	2015-05-13
HUE024962T2 (en)	2016-02-29
AU2005320349C1 (en)	2019-06-13
BRPI0507433B8 (pt)	2018-04-10
CN101014620A (zh)	2007-08-08
DK2270045T3 (en)	2015-04-07
EP1766093A2 (en)	2007-03-28
PT2270045E (pt)	2015-04-08
NZ580828A (en)	2011-09-30
AU2005320349B2 (en)	2010-04-08
NO20063767L (no)	2006-10-02
NO2017032I1 (no)	2017-07-07
HUE034552T2 (en)	2018-02-28
PT2857418T (pt)	2017-10-20
BRPI0507433C1 (pt)	2021-05-25
PL1766093T3 (pl)	2011-11-30
WO2006121422A3 (en)	2007-03-15
US20050287150A1 (en)	2005-12-29
CY1119416T1 (el)	2018-03-07
BRPI0507433A (pt)	2007-07-03

Publication	Publication Date	Title
HRP20110599T1 (hr)	2011-10-31	Antitijela protiv toksina clostridium difficile i njihove primjene
HRP20210876T1 (hr)	2021-07-09	Anti-tmprss2 antitijela i fragmenti koji vezuju antigen
HRP20120701T1 (hr)	2012-10-31	Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2018510636A5 (ja)	2019-02-21
RU2013125306A (ru)	2014-12-10	Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
RU2015142815A (ru)	2017-04-12	Лечение рака с использованием антител, связывающихся с поверхностным grp78
RU2016100892A (ru)	2017-07-19	Антитела против tweakr и их применение
CN107428832A (zh)	2017-12-01	抗pd‑l1抗体
RU2016129113A (ru)	2018-01-25	Антитела к pd-1 собак
JPWO2019175220A5 (ja)	2022-03-18
JPWO2019175217A5 (ja)	2022-03-18
JPWO2019175216A5 (ja)	2022-03-18
JPWO2019175215A5 (ja)	2022-03-18
RU2013125459A (ru)	2014-12-10	АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
RU2012103212A (ru)	2013-08-20	Tlr3 связывающие агенты
RU2015144105A (ru)	2017-04-24	Антитела к гепсидину и их применения
JPWO2019175222A5 (ja)	2022-03-18
JP2014529610A5 (ja)	2015-10-15
WO2015191934A2 (en)	2015-12-17	Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
RU2012137380A (ru)	2014-03-10	Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи
HRP20192038T1 (hr)	2020-02-07	Protutijela receptora anti-epidermalnog faktora rasta (egfr)
IL259036A (en)	2018-06-28	asct2-specific binding molecules and their uses
JP2016501877A5 (ja)	2017-01-12
JP2017521054A5 (ja)	2018-07-12
JP2020522280A5 (ja)	2021-07-26